Patents Assigned to Astex Therapeutics
  • PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES
    Publication number: 20130184285
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: March 6, 2013
    Publication date: July 18, 2013
    Applicants: ASTEX THERAPEUTICS, NOVARTIS AG
    Inventors: NOVARTIS AG, ASTEX THERAPEUTICS
  • Substituted pyrrolo[3,4-b]pyridinamines and pharmaceutical compositions
    Patent number: 7629356
    Abstract: This invention relates to substituted pyrrolo[3,4-b]pyridinamines having the structural formula IA below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: December 8, 2009
    Assignees: AstraZeneca AB, Astex Therapeutics
    Inventors: Gianni Chessari, Miles Stuart Congreve, Jörg Holenz, Christopher Murray, Sahil Patel, Laszlo Rakos, Didier Rotticci